IC
ELVN icon

Ikarian Capital’s Enliven Therapeutics ELVN Stock Holding History

Ikarian Capital’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-289,538
Closed -$5.7M – 156
2025
Q1 		$5.7M Sell
289,538
-105,000
-27% -$2.26M 0.7% 31
2024
Q4 		$8.88M Sell
394,538
-105,028
-21% -$2.72M 1.21% 17
2024
Q3 		$12.8M Sell
499,566
-86,986
-15% -$2.01M 1.78% 11
2024
Q2 		$13.7M Buy
+586,552
New +$12.3M 2.39% 14

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ikarian Capital's ELVN Position: Q2 2025 in Review

Ikarian Capital sold out of Enliven Therapeutics (ELVN) in Q2 2025, closing a stake of 289,538 shares — an estimated $5.7M sold.

Ikarian Capital first reported a position in ELVN in Q2 2024 and held it in 4 quarters. The position peaked at $13.7M in Q2 2024. 124 funds tracked by Wall St. Rank hold ELVN as of Q2 2025.

  • Ikarian Capital reported no remaining Enliven Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ikarian Capital sold 289,538 Enliven Therapeutics shares in Q2 2025, an estimated $5.7M.
  • Ikarian Capital first reported a position in Enliven Therapeutics in Q2 2024 and held it in 4 quarters.
  • Ikarian Capital's Enliven Therapeutics position peaked at $13.7M in Q2 2024.
  • 124 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.